Danan Gaby, Teschke Rolf
Pharmacovigilance Consultancy, rue des Ormeaux, 75020 Paris, France.
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Frankfurt am Main, D-63450 Hanau, Germany.
Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014.
RUCAM (Roussel Uclaf Causality Assessment Method) or its previous synonym CIOMS (Council for International Organizations of Medical Sciences) is a well established tool in common use to quantitatively assess causality in cases of suspected drug induced liver injury (DILI) and herb induced liver injury (HILI). Historical background and the original work confirm the use of RUCAM as single term for future cases, dismissing now the term CIOMS for reasons of simplicity and clarity. RUCAM represents a structured, standardized, validated, and hepatotoxicity specific diagnostic approach that attributes scores to individual key items, providing final quantitative gradings of causality for each suspect drug/herb in a case report. Experts from Europe and the United States had previously established in consensus meetings the first criteria of RUCAM to meet the requirements of clinicians and practitioners in care for their patients with suspected DILI and HILI. RUCAM was completed by additional criteria and validated, assisting to establish the timely diagnosis with a high degree of certainty. In many countries and for more than two decades, physicians, regulatory agencies, case report authors, and pharmaceutical companies successfully applied RUCAM for suspected DILI and HILI. Their practical experience, emerging new data on DILI and HILI characteristics, and few ambiguous questions in domains such alcohol use and exclusions of non-drug causes led to the present update of RUCAM. The aim was to reduce interobserver and intraobserver variability, to provide accurately defined, objective core elements, and to simplify the handling of the items. We now present the update of the well accepted original RUCAM scale and recommend its use for clinical, regulatory, publication, and expert purposes to validly establish causality in cases of suspected DILI and HILI, facilitating a straightforward application and an internationally harmonized approach of causality assessment as a common basic tool.
RUCAM(鲁塞尔·优克福因果关系评估方法)或其前身同义词CIOMS(国际医学科学组织理事会)是一种广泛使用的成熟工具,用于定量评估疑似药物性肝损伤(DILI)和草药性肝损伤(HILI)病例中的因果关系。历史背景和原始工作证实,为了简洁明了,今后将使用RUCAM这一术语,不再使用CIOMS。RUCAM是一种结构化、标准化、经过验证且针对肝毒性的诊断方法,对各个关键项目进行评分,为病例报告中的每种可疑药物/草药提供最终的因果关系定量分级。欧洲和美国的专家此前在共识会议上制定了RUCAM的首批标准,以满足临床医生和从业者对疑似DILI和HILI患者的护理需求。RUCAM通过附加标准得以完善并经过验证,有助于高度确定地及时做出诊断。在许多国家,二十多年来,医生、监管机构、病例报告作者和制药公司成功地将RUCAM应用于疑似DILI和HILI。他们的实践经验、DILI和HILI特征方面新出现的数据,以及酒精使用和非药物原因排除等领域中一些模糊的问题,促成了RUCAM的此次更新。目的是减少观察者间和观察者内的变异性,提供准确定义的客观核心要素,并简化项目处理。我们现在展示广为人知的原始RUCAM量表的更新版本,并推荐将其用于临床、监管、出版和专家目的,以便在疑似DILI和HILI病例中有效确定因果关系,促进作为通用基本工具的因果关系评估的直接应用和国际协调方法。